arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Edwards Lifesciences Corp

EW
$89.69 ▲ +0.38 (+0.42%) at close
Healthcare ·Orthopedic, Prosthetic & Surgical Appliances & Supplies ·USOrthopedic, Prosthetic & Surgical Appliances & Supplies
71 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
78
Health
Good
Bullish
auto_awesome

Analytical Summary

Edwards Lifesciences Corp shows strong fundamentals with top-quartile Profit Margin (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $51.9B
Dividend Yield
Revenue Growth 16.7%
Op. Margin 29.0%
ROIC 3.6%
FCF / Share $-0.04
Trailing P/E 135.9x
Price / Book 5.0x
FCF Yield
Debt / Equity 0.06
info Valuation on last close. End-of-day price, Aug 7, 2026.

71-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.65B
↑ +16.7%
Net Income Profit after all expenses
$380.70M
↑ +6.3%
Operating Margin Operating profit as % of sales
29.0%
↑ +200.9% 77th
FCF / Share Free cash flow per share
$-0.04
↓ -104.1%
Long-Term Debt Long-term obligations
$598.50M
— 0.0%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
80
Returns
69
Financial Health
90
Cash Quality
74

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 19 years · 71 quarters